Aim:

To assess the efficacy and safety of tadalafil in comparison to a placebo, when taken on demand for 12 weeks by East/Southeast Asian men with erectile dysfunction (ED).

Methods:

This multicenter, randomized, double-blind, parallel group, placebo-controlled study was conducted at 17 centers across East and Southeast Asia between August 2002 and February 2003. Men more than 18 years of age with mild to severe ED of various etiologies were randomized to receive a placebo or 20 mg of tadalafil taken as needed (maximum once daily). Efficacy assessments included the International Index of Erectile Function, the Sexual Encounter Profile diary and Global Assessment Questions.

Results:

Tadalafil significantly improved erectile function as compared to the placebo (P < 0.001). At the endpoint, the patients receiving 20 mg of tadalafil reported a greater mean per patient percentage of successful intercourse attempts (Sexual Encounter Profile question 3: 70.9% compared to 33.5% in the placebo) and a greater proportion of improved erections (Global Assessment Question: 86.2% compared to 30.1%). Most ( 3%) treatment emergent adverse events were mild or moderate. The most common treatment emergent adverse events were headache, back pain, dizziness and dyspepsia.

Conclusion:

Tadalafil was an effective and well-tolerated treatment for ED in East and Southeast Asian men.

References

1. Saenz de Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 1989; 320: 1025–30. | PubMed | ChemPort |
2. Shabsigh R, Fishman IJ, Schum C, Dunn JK. Cigarette smoking and other vascular risk factors in vasculogenic impotence. Urology 1991; 38:227–31. | Article | PubMed | ISI | ChemPort |
3. Kubin M, Wagner G, Fugl-Meyer AR. Epidemiology of erectile dysfunction. Int J Impot Res 2003; 15: 63–71. | Article | PubMed | ISI | ChemPort |
4. McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000; 12 (Suppl 4): S6–S11. | Article | PubMed | ISI |
5. NIH Consensus Development Panel on Impotence. NIH Consensus Conference. Impotence. JAMA 1993; 270: 83–90. | PubMed | ISI |
6. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. B J U Int 1999; 84: 50–6. | ChemPort |
7. Meuleman EJ, Lycklama a Nijeholt G, Slob K, Roeleveld X, Damen L, deBrazao GC, et al. Effects of IC351 on erectile response to visual stimulation. J Urol 1999; 161 (Suppl 4): 212. | Article | PubMed |
8. Juilfs DM, Soderling S, Burns F, Beavo JA. Cyclic GMP as substrate and regulator of cyclic nucleotide phosphodiesterases (PDEs). Rev Physiol Biochem Pharmacol 1999; 135: 67–104. | PubMed | ChemPort |
9. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1332–6. | Article | PubMed | ISI | ChemPort |
10. Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003; 62: 121–5. | Article | PubMed | ISI |
11. Patterson B, Bedding A, Jewell H, Payne C, Mitchell M. The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351). Int J Impot Res 2001; 13 (Suppl 4): 43–4.
12. Carson CC, Rajfer J, Eardley I, Carrier S, Dennes JS, Walkers DJ, et al. The efficacy and safety of tadalafil: an update. BJU Int 2004; 93: 1276–81. | Article | PubMed | ISI | ChemPort |
13. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–30. | Article | PubMed | ISI | ChemPort |
14. Cappelleri JC, Siegel RL, Osterloh IH, Rosen RC. Relationship between patient self-assessment of erectile function and the erectile function domain of the international index of erectile function. Urology 2000; 56: 477–81. | Article | PubMed | ISI | ChemPort |
15. Tan HM, Moh CL, Mendoza JB, Gana T, Albano GJ, de la Cruz R, et al. Asian sildenafil efficacy and safety study (ASSESS-1): a double-blind, placebo-controlled, flexible-dose study of oral sildenafil in Malaysian, Singaporean, and Filipino men with erectile dysfunction. The Assess-1 Study Group. Urology 2000; 56: 635–40. | Article | PubMed | ISI | ChemPort |
16. Chen KK, Hsieh JT, Huang ST, Jiaan DB, Lin JS, Wang CJ. ASSESS 3: A randomized, double blind, flexible dose clinical trial of the efficacy and safety of oral sildenafil in the treatment of men with erectile dysfunction in Taiwan. Int J Impot Res 2001; 13: 221–9. | Article | PubMed | ISI | ChemPort |
17. Leung KF, Giroudet C. Cross-cultural adaptation of the International index of Erectile Function (IIEF). Int J Impot Res 1997; 9 (Suppl. 1): S47. | Article |
18. Chen KK, Jiann BP, Lin JS, Lee SS, Huang ST, Wang CJ, et al. Efficacy and safety of on-demand oral tadalafil in the treatment of men with erectile dysfunction in Taiwan: a randomized, double blind, parallel, placebo-controlled clinical study. J Sex Med 2004; 1: 201–8. | Article | PubMed | ChemPort |
19. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sidenafil Study Group. N Engl J Med 1998; 338: 1397–404. | Article | PubMed | ISI | ChemPort |
20. Montorsi F, Verheyden B, Meuleman E, Junemann KP, Moncada I, Valiquette L, et al. Long-term safety and tolerability of tadalfil in the treatment of erectile dysfunction. Eur Urol 2004; 45: 339–45. | Article | PubMed | ISI | ChemPort |

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.